TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02061098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-first dose-Group A
Description: Group A will consume 1 daily capsule of pomegranate extract for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-first dose-Group B
Description: Group B will consume 1 daily capsules of placebo for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-first dose-Group B
Description: After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-first dose-Group A
Description: After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-second dose-Group A
Description: After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-second dose-Group B
Description: After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-second dose-Group B
Description: After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-second dose-Group A
Description: After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
Study: NCT02456662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
Study: NCT02422485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
Study: NCT01159379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: intravenous, 1 gram, once
Study: NCT04547049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 4 mg/m2/day administered IV day -10 through -9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 4 mg/m2/day administered IV day -10 through -9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 3.2 mg/kg/day administered IV day -8 through -6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 3.2 mg/kg/day administered IV day -8 through -6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1.8 g/m2/day administered IV day -5 through -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1.8 g/m2/day administered IV day -5 through -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Me-CCNU
Description: 250mg/m2 once administered orally on day -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Me-CCNU
Description: 250mg/m2 once administered orally on day -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit antithymocyte globulin
Description: 1.5mg/kg/day administered IV day -5 through -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit antithymocyte globulin
Description: 1.5mg/kg/day administered IV day -5 through -2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: 15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: 15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
Study: NCT03142438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Seal Improvement Project
Description: Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
Study: NCT02496910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine 80/5 mg (FDC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine 80/5 mg (FDC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Study: NCT00919555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone and Tretinoin
Description: Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin and Pioglitazone HCL
Description: Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03318939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID
Study: NCT05408104

Intervention type: DRUG
Intervention: tolvaptan
Description: LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
Study: NCT04398641

Intervention type: OTHER
Intervention: Evaluation of pre- and postoperative gastrointestinal functional outcomes
Description: Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.

Intervention type: OTHER
Intervention: Evaluation of pre- and postoperative gastrointestinal functional outcomes
Description: Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
Study: NCT04569383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-S vaccinations (days 0 & 28)
Description: Vaccination with MVA-SARS-2-S in two escalating dose regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-S vaccinations (days 0 & 28)
Description: Vaccination with MVA-SARS-2-S in two escalating dose regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: Vaccination with Comirnaty (21 day interval)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: Vaccination with Comirnaty (21 day interval)
Study: NCT04470609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 28-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,28
Study: NCT03457454

Intervention type: OTHER
Intervention: Primary Care Provider/Staff Participants Interview
Description: -Approximately a 30 minute interview

Intervention type: OTHER
Intervention: Patient Participant Interview
Description: -Approximately 45-60 minute interview

Intervention type: OTHER
Intervention: Patient Participant Anonymous Survey
Description: -Survey completion will take approximately 15 minutes

Intervention type: OTHER
Intervention: Colonoscopy Provider/Staff Participants Interviews
Description: -Approximately a 30 minute interview
Study: NCT02475486

Intervention type: DEVICE
Group type: OTHER
Intervention: VistaO2
Description: ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients

Intervention type: DEVICE
Group type: OTHER
Intervention: VistaO2
Description: ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
Study: NCT03006354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHFOV
Description: Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
Study: NCT02981446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Study: NCT00583570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary education
Description: dietary education
Study: NCT00339170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Based Cognitive Enhancement Training Program
Description: Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Therapy Program
Description: Participants in the work therapy program will attend two non-cognitive discussion groups per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work Therapy Program
Description: Participants in the work therapy program will attend two non-cognitive discussion groups per week.
Study: NCT05057286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical crown lengthening surgery
Description: * Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection.
Study: NCT04758182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
Study: NCT06360562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Training
Description: Behavioral group-based intervention delivering mindfulness, metallization, and self-compassion skills.
Study: NCT04556058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril tert-Butylamine tablets （ Produced by Haisco）
Description: The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril tert-Butylamine tablets（ACERTIL®）
Description: The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
Study: NCT02257216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vayarin®
Description: Medical Food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vayarin®
Description: Medical Food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Cellulose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study: NCT02211352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Capsules
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Study: NCT02810899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
Study: NCT04575480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy for renal stone.
Description: The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy for renal stone.
Description: The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy for renal stone.
Description: The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
Study: NCT02488889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill (for varenicline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo beverage (for alcohol)
Study: NCT03576703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with and without SSB ingestion
Description: Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with and without SSB ingestion
Description: Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
Study: NCT04326647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: We used kinesiotaping in gastrocnemius and lumbar back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises about balance and gait
Study: NCT03017274

Intervention type: OTHER
Intervention: Abdominal ultrasound examination
Description: All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.

Intervention type: OTHER
Intervention: Abdominal ultrasound examination
Description: All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
Study: NCT04478656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
Study: NCT02869776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Behavioral questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Behavioral questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid finger stick
Description: HIV and HCV testing through rapid finger stick

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: HIV and HCV testing through venipuncture
Study: NCT00906360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally or by percutaneous gastrostomy tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study: NCT01390181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cozaar
Description: Angiotensin II Receptor Blocker